Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration

2013496 citationsJournal Articlehybrid Open Access

Authors

Proprietary or commercial disclosure may be found after the references.

Good health and well-being

Published in: Ophthalmology

Volume 120, Issue 5, pp. 1046-1056

Field-Weighted Citation Impact: 37.54